

**Amendments to the Specification**

On page 32, replace the 7<sup>th</sup> paragraph (Page 32, lines 18-20) with the following new paragraphs:

Figure 5A shows the reduction in the incidence of virus shedding in mice immunized with HSV-1/rEtxB.

Figure 5B shows the reduction in the incidence of clinical disease and latency in mice immunized with HSV-1/rEtxB.

On page 33, replace the 10<sup>th</sup> paragraph (Page 33, lines 35-Page 34 line8 with the following new paragraph (correcting the word “plycoproteins” with “glycoproteins”):

Mice were immunized intranasally three times with 10 $\mu$ g HSV-1 glycoproteins (Gp) with either 10 or 20  $\mu$ g rEtxB. Controls were either unmanipulated or given a mock preparation of viral glycoprotein (mock) derived from HIV-uninfected tissue culture cells. Antibody levels are expressed as a percentage of post-infection levels. The production of total Ig and IgA in the serum and IgA in eye washings was stimulated by HSV-1 glycoproteins/rEtxB (Figure 1). The present inventors have also shown that doses of rEtxB as low as 0.1  $\mu$ g are also effective at stimulating such responses.